GFAP and COVID-19: This is the first Brazilian study considering mild and severe COVID-19 patients investigated simultaneously by four biomarkers (NfL, GFAP, TAU, and UCH-L1), biochemical parameters, viral load, comorbidities, and outcome analysis.